Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 1998;98:2702-2708

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Darbar, D.
Right arrow Articles by Roden, D. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Darbar, D.
Right arrow Articles by Roden, D. M.

(Circulation. 1998;98:2702-2708.)
© 1998 American Heart Association, Inc.


Clinical Investigation and Reports

Modulation by Dietary Salt of Verapamil Disposition in Humans

Dawood Darbar, MD; Martin F. Fromm, MD; Simonetta Dell'Orto, MD; Richard B. Kim, MD; Heyo K. Kroemer, PhD; Michel Eichelbaum, MD; Dan M. Roden, MD

From the Departments of Medicine and Pharmacology, Vanderbilt University School of Medicine, Nashville, Tenn (D.D., M.F.F., S.D., R.B.K., D.M.R.); the Dr Margarete Fischer-Bosch-Institut für Klinische Pharmakologie, Stuttgart, Germany (M.F.F., H.K.K., M.E.); and the Abteilung für Klinische Pharmakologie, Eberhard-Karls-Universität, Tübingen, Germany (M.E.). Dr Kroemer is now Chair of the Department of Pharmacology, University of Greifswald, Germany.

Correspondence to Dan M. Roden, MD, Director, Division of Clinical Pharmacology, 532 Medical Research Building-I, Vanderbilt University School of Medicine, Nashville, TN 37232-6602. E-mail dan.roden{at}mcmail.vanderbilt.edu

Background—The intestine is an increasingly well-recognized site of first-pass drug metabolism. In this study, we determined the influence of dietary salt on the steady-state disposition of verapamil, a drug that undergoes extensive first-pass metabolism.

Methods and Results—Eight normal volunteers received 120 mg of racemic verapamil orally twice a day for 21 days. The disposition kinetics of verapamil enantiomers were determined after coadministration of intravenous deuterated verapamil with the morning oral dose on days 7, 14, and 21. Each study day was preceded by 7 days on a fixed-salt diet: in 5 subjects, the initial study was conducted during a low-salt (10 mEq/d) diet, the second study during a high-salt (400 mEq/d) diet, and the third during a low-salt diet, whereas in the other 3 subjects, the sequence of diets was reversed. Plasma concentrations of both unlabeled enantiomers (ie, from oral therapy) were significantly (P<0.05) lower during the high-salt phase (eg, mean area under the time-concentration curve [0 to 12 hours] for S-verapamil: 7765±2591 ng · min · mL-1 [high salt] versus 12 514±3527 ng · min · mL-1 [low salt], P<0.05). Peak plasma concentrations were significantly lower and the extent of PR interval prolongation significantly blunted with the high-salt diet. In contrast, data with labeled drug (ie, reflecting the intravenous route) were nearly identical for the 2 diets.

Conclusions—These data indicate that a clinically important component of presystemic drug disposition occurs at the prehepatic (presumably intestinal) level and is sensitive to dietary salt.


Key Words: diet • metabolism • sodium • stereoisomers




This article has been cited by other articles:


Home page
Mol. Pharmacol.Home page
K. Kosuge, A. I. Chuang, S. Uematsu, K. P. Tan, K. Ohashi, B. C.B. Ko, and S. Ito
Discovery of Osmosensitive Transcriptional Regulation of Human Cytochrome P450 3As by the Tonicity-Responsive Enhancer Binding Protein (Nuclear Factor of Activated T Cells 5)
Mol. Pharmacol., October 1, 2007; 72(4): 826 - 837.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
R. K. Bhardwaj, H. Glaeser, L. Becquemont, U. Klotz, S. K. Gupta, and M. F. Fromm
Piperine, a Major Constituent of Black Pepper, Inhibits Human P-glycoprotein and CYP3A4
J. Pharmacol. Exp. Ther., August 1, 2002; 302(2): 645 - 650.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
C. Pauli-Magnus, O. von Richter, O. Burk, A. Ziegler, T. Mettang, M. Eichelbaum, and M. F. Fromm
Characterization of the Major Metabolites of Verapamil as Substrates and Inhibitors of P-glycoprotein
J. Pharmacol. Exp. Ther., May 1, 2000; 293(2): 376 - 382.
[Abstract] [Full Text]


Home page
J. Pharmacol. Exp. Ther.Home page
M. F. Fromm, D. Darbar, S. Dell'Orto, and D. M. Roden
Modulation of Effect of Dietary Salt on Prehepatic First-Pass Metabolism: Effects of beta -Blockade and Intravenous Salt Loading
J. Pharmacol. Exp. Ther., July 1, 1999; 290(1): 253 - 258.
[Abstract] [Full Text]